<DOC>
	<DOC>NCT02960945</DOC>
	<brief_summary>This study will assess the metabolite and pharmacokinetic (PK) profile of a single dose of CTP-543 compared to a single dose of Jakafi® in healthy volunteers.</brief_summary>
	<brief_title>Open-Label Crossover Study Comparing CTP-543 to Jakafi®</brief_title>
	<detailed_description>The crossover design will assess the safety, tolerability, PK and metabolite profiles of a single dose of CTP-543 compared to a single dose of Jakafi. Approximately 12 healthy volunteers will be enrolled in this open label study.</detailed_description>
	<criteria>Healthy adult males and females between 18 and 50 years of age, inclusive Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions PR interval &gt; 220 msec or QRS duration &gt; 120 msec or QTcF interval &gt; 450 msec obtained at screening visit or prior to the first dose of study drug History of herpes zoster Hemoglobin, white blood cell, or platelet levels below the lower reference limit at screening or prior to the first dose of study drug Liver function tests greater than the upper limit of normal Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody Urinalysis positive for protein or glucose A positive screen for alcohol, drugs of abuse, or tobacco use Donation of blood, plasma or other blood products prior to screening A positive tuberculosis test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>